Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Radioiodine (131I) therapy of benign thyroid diseases was introduced 70 yr ago, and the
patients treated since then are probably numbered in the millions. Fifty to 90% of …

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Context: Radioiodine ablation of the thyroid remnant after thyroidectomy is commonly
performed in the management of patients with differentiated thyroid cancer. Although many …

The most frequent thyroid cancer is Differentiated Thyroid Cancer (DTC) representing more
than 95% of cases. A suitable choice for the treatment of DTC is the systemic administration …

The treatment of differentiated thyroid cancer continues to move away from a 'one size fits
all'approach to a process of tailored therapeutic decision-making that incorporates disease …

Differentiated thyroid carcinoma (DTC) has been increasing in incidence in the United
States over the last several decades, although mortality rates have remained low …

Radioiodine (RAI) is selectively recommended for intermediate-risk differentiated thyroid
carcinomas (DTC). The information gleaned from pretherapy stimulated thyroglobulin levels …

Objective: Dosimetry studies have shown that activities of 131 I as small as 10-20 MBq may
cause a stunning effect. A result of this stunning effect may be a lower success rate of the …

Context: Published studies of thyroid stunning due to preablation 131I scanning in the
treatment of differentiated thyroid cancer after thyroidectomy had shown inconsistent clinical …